Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to February 2003

February 2003

A 20th Anniversary


1. Li R, et al. Trends in fruit and vegetable consumption among adults in 16 US states: Behavioral Risk Factor Surveillance System, 1990-1996. Am J Public Health 2000 May;90(5):777-81.

2. Walaszek Z, et al. D-glucaric acid content of various fruits and vegetables and cholesterol-lowering effects of dietary D-glucarate in the rat. Nutrition Research (United States) 1996, 16/4 (673-681).

3. Dwivedi C, et al. Effect of calcium glucarate on beta-glucoronidase activity and glucarate content of certain vegetable and fruits. Biochemical Medicine and Metabolic Biology (United States) 1990, 43/2 (83-92).

4. Loarca-Pina G, et al. Inhibitory effects of ellagic acid on the direct-acting mutagenicity of aflatoxin B1 in the Salmonella microsuspension assay. Mutat Res 1998 Feb 26;398(1-2):183-7.

5. Maas, J. L, et al. Ellagic acid, an anticarcinogen in fruits, especially in strawberries: a review. HortScience vol. 26 (1): p.10-14, 1991.

6. Constantinou A, et al. The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro. Nutrition and Cancer (United States) 1995, 23/2 (121-130).

7. Stoner GD, et al. Lung tumors in strain A mice: application for studies in cancer chemoprevention. J Cell Biochem Suppl 1993;17F:95-103.

8. Barch DH, et al. Ellagic acid induces NAD(P)H:quinone reductase through activation of the antioxidant responsive element of the rat NAD(P)H:quinone reductase gene. Carcinogenesis 1994 Sep;15(9):2065-8.

9. Teel R.W, et al. Ellagic acid metabolism and binding to DNA in organ explant cultures of the rat. Cancer Letters (Ireland) 1987, 36/2 (203-211).

10. Barch D.H, et al. Structure-function relationships of the dietary anticarcinogen ellagic acid. Carcinogenesis (United Kingdom) 1996, 17/2 (265-269).

11. Teel R.W. Ellagic acid binding to DNA as a possible mechanism for its antimutagnic and anticarcinogenic action. ­Cancer Letters (Ireland) 1986, 30/3 (329-336).

12. Soni K.B, et al. Protective effect of food additives on aflatoxin-induced mutagenicity and hepatocarcinogenicity. Cancer Letters (Ireland) 1997, 115/2 (129-133).

13. Dixit R, et al. Inhibition of N-methyl-N-nitrosourea-induced mutagenicity and DNA methylation by ellagic acid. Proceedings of the National Academy of Sciences of the United States of America (United States) 1986, 83/21 (8039-8043).

14. Stoner GD, et al. Polyphenols as cancer chemopreventive agents. J Cell Biochem Suppl 1995;22:169-80.

15. Teel R.W, et al. Antimutagenic effects of polyphenolic compounds. Cancer Letters (Ireland) 1992, 66/2 (107-113).

16. Wilson T, et al. The effect of ellagic acid on xenobiotic metabolism by cytochrome P-450IIE1 and nitrosodimethylamine mutagenicity. Cancer Letters (Ireland) 1992, 61/2 (129-134).

17. Narayanan B.A, et al. p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Letters (Ireland) 1999, 136/2 (215-221).

18. Stoner GD, et al. Lung tumors in strain A mice: application for studies in cancer chemoprevention. J Cell Biochem Suppl 1993;17F:95-103.

19. Teel R.W, et al. Ellagic acid metabolism and binding to DNA in organ explant cultures of the rat. Cancer Letters (Ireland) 1987, 36/2 (203-211).

20. Stoner GD, et al. Polyphenols as cancer chemopreventive agents. J Cell Biochem Suppl 1995;22:169-80.

21. Castonguay A. Pulmonary carcinogenesis and its prevention by dietary polyphenolic compounds. Ann N Y Acad Sci 1993 May 28;686:177-85.

22. Stoner G.D, et al. Isothiocyanates and plant polyphenols as inhibitors of lung and esophageal cancer. Cancer Letters (Ireland) 1997, 114/1-2 (113-119).

23. Loarca-Pina G, et al. Antimutagenicity of ellagic acid against aflatoxin Binf 1 in the Salmonella microsuspension assay. Mutation Research - Environmental Mutagenesis and Related Subjects (Netherlands) 1996, 360/1 (15-21).

24. Barch D.H, et al. Dietary ellagic acid reduces the esophageal microsomal metabolism of methylbenzylnitrosamine. Cancer Letters (Ireland) 1989, 44/1 (39-44).

25. Castonguay A, et al. Antitumorigenic and antipromoting activities of ellagic acid, ellagitannins and oligomeric anthocyanin and procyanidin International Journal of Oncology (Greece) 1997, 10/2 (367-373).

26. Rao C.V, et al. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Research 1991, 51/17 (4528-4534).

27. Bradlow HL, et al. Phytochemicals as modulators of cancer risk. Adv Exp Med Biol 1999;472:207-21.

28. Kelloff GJ, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000 Feb;130(2S Suppl):467S-471S.

29. Wang X, et al. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase. Br J Cancer 1999 Jun;80(8):1223-30.

30. Lee SK, et al. Modulation of in vitro biomarkers of the carcinogenic process by chemopreventive agents. Anticancer Res 1999 Jan-Feb;19(1A):35-44.

31. Hecht SS, et al. Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. J Nutr 1999 Mar;129(3):768S-774S.

32. Zhang Y, et al. Mechanism of differential potencies of isothiocyanates as inducers of anticarcinogenic Phase 2 enzymes. Cancer Res 1998 Oct 15;58(20):4632-9.

33. Kelloff GJ, et al. New agents for cancer chemoprevention. J Cell Biochem Suppl 1996;26:1-28.

34. Gamet-Payrastre L, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 2000 Mar 1;60(5):1426-33.

35. Kong AN, et al. Signal transduction events elicited by natural products: role of MAPK and caspase pathways in homeostatic response and induction of apoptosis. Arch Pharm Res 2000 Feb;23(1):1-16.

36. Zhang Y. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. Carcinogenesis 2000 Jun;21(6):1175-1182.

37. Singletary K, et al. Inhibition of benzo[a]pyrene- and 1,6-dinitropyrene-DNA adduct formation in human mammary epithelial cells bydibenzoylmethane and sulforaphane. Cancer Lett 2000 Jul 3;155(1):47-54.

38. Kopelovich L, et al. Progress in cancer chemoprevention. Ann N Y Acad Sci 1999;889:1-13.

39. Yu R, et al. p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J Biol Chem 2000 Jan 28;275(4):2322-7.

40. Hirano T, et al. Antiproliferative effects of synthetic and naturally occurring flavonoids on tumor cells of the human breast carcinoma cell line, ZR-75-1. Res Commun Chem Pathol Pharmacol 1989 Apr;64(1):69-78.

41. Kuiper GG, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998 Oct;139(10):4252-63.

42. Ma JY, et al. A sesquiterpene lactone glucoside from Ixeris denticulata f. pinnatipartita. Phytochemistry 1999 Jan;50(1):113-5.

43. Holland MB, et al. Estrone-induced cell proliferation and differentiation in the mammary gland of the female Noble rat. Carcinogenesis 1995 Aug;16(8):1955-61.

44. Wang C, et al. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol 1994 Aug;50(3-4):205-12.

45. Frank SA, et al. Effects of aging on glucose regulation during wakefulness and sleep. Am J Physiol 1995 Dec;269(6 Pt 1):E1006-16.

46. Stout RW. Glucose tolerance and ageing. J R Soc Med 1994 Oct;87(10):608-9.

47. Morganti P, et al. Gelatin-cystine, keratogenesis and structure of the hair. Boll Soc Ital Biol Sper 1983 Jan 31;59(1):20-5.

48. Hochman L.G, et al. Brittle nails: Response to daily biotin supplementation. Cutis (United States) 1993, 51/4 (303-305).

49. Bardazzi F, et al. Biotin in the treatment of idiopathic brittle nails. Giornale Italiano di Dermatologia e Venereologia (Italy) 1993, 128/12 (699-702).

50. Zhang H, et al. Biotin administration improves the impaired glucose tolerance of streptozotocin-induced diabetic Wistar rats. J Nutr Sci Vitaminol (Tokyo) 1997 Jun;43(3):271-80.

51. Furukawa Y. Enhancement of glucose-induced insulin secretion and modification of glucose metabolism by biotin. [Article in Japanese] Nippon Rinsho 1999 Oct;57(10):2261-9.

52. McCarty MF. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes. Med Hypotheses 1999 May;52(5):401-6.

53. Haulica I, et al. Implications of oxidative stress in senescence.[Article in Romanian] Rev Med Chir Soc Med Nat Iasi 2000 Apr-Jun;104(2):15-9.

54. Ceconi C, et al. The role of glutathione status in the protection against ischaemic and reperfusion damage: effects of N-acetyl cysteine. J Mol Cell Cardiol 1988 Jan;20(1):5-13.

55. Baas P, et al. Effect of N-acetylcysteine on Photofrin-induced skin photosensitivity in patients. Lasers Surg Med 1995;16(4):359-67.

56. Urban T, et al. Neutrophil function and glutathione-peroxidase (GSH-px) activity in healthy individuals after treatment with N-acetyl-L-cysteine. Biomed Pharmacother 1997;51(9):388-90.

57. Baik HW, et al. Vitamin B12 deficiency in the elderly. Annu Rev Nutr 1999;19:357-77.

58. Loew D, et al. Studies on vitamin B12 status in the elderly--prophylactic and therapeutic consequences. Int J Vitam Nutr Res 1999 May;69(3):228-33.

59. Bachli E, et al. [Diagnosis of vitamin B12 deficiency: only apparently child's play]. Schweiz Med Wochenschr 1999 Jun 12;129(23):861-72.

60. Carr AC, Tijerina T, Frei B. Vitamin C protects against and reverses specific hypochlorous acid- and chloramine-dependent modifications of low-density lipoprotein. Biochem J 2000 Mar 1;346 Pt 2:491-9.

61. Romani AM, et al. Regulation of cellular magnesium. Front Biosci 2000 Aug 1;5:D720-34.

62. Saatman KE, et al. Acute cytoskeletal alterations and cell death induced by experimental brain injury are attenuated by magnesium treatment and exacerbated by magnesium deficiency. J Neuropathol Exp Neurol 2001 Feb;60(2):183-94.

63. Girodon F, et al. Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients: a randomized controlled trial. MIN. VIT.AOX. geriatric network. Arch Intern Med 1999 Apr 12;159(7):748-54.

64. Brod SA. Unregulated inflammation shortens human functional longevity. Inflamm Res 2000 Nov;49(11):561-70.

65. Ward PA. Cytokines, inflammation, and autoimmune diseases. Hosp Pract (Off Ed) 1995 May 15;30(5):35-41

66. Rintala RJ, et al. Sodium cromoglycate in the management of chronic or recurrent enterocolitis in patients with Hirschsprung's disease. J Pediatr Surg 2001 Jul;36(7):1032-5.

67. Kiechl S, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001 Feb 27;103(8):1064-70.

68. Ip C, et al. Methylselenocysteine modulates proliferation and apoptosis biomarkers in premalignant lesions of the rat mammary gland. Anticancer Res. 2001 Mar-Apr;21(2A):863-7.

69. Lu J, et al. Effect on an aqueous extract of selenium-enriched garlic on in vitro markers and in vivo efficacy in cancer prevention. Carcinogenesis 1996 Sep;17(9):1903-7.

70. Sinha R, et al. Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and gadd gene expression in synchronized mouse mammary epithelial tumor cells. Cancer Lett. 1999 Nov 15;146(2):135-45.

71. Sinha R, et al. Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial tumor cells. Carcinogenesis 1997 Aug;18(8):1541-7.

72. Yeo JK, et al. Se-methylselenocysteine induces apoptosis through caspase activation and Bax cleavage mediated by calpain in SKOV-3 ovarian cancer cells. Cancer Lett 2002 Aug 8;182(1):83-92.

73. Jung U, et al. Se-methylselenocysteine induces apoptosis mediated by reactive oxygen species in HL-60 cells. Free Radic Biol Med. 2001 Aug 15;31(4):479-89.

74. Jiang C, et al. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 1999 Dec;26(4):213-25.

75. Whanger PD, et al. Tumorigenesis, metabolism, speciation, bioavailability, and tissue deposition of selenium in selenium-enriched ramps (Allium tricoccum). J Agric Food Chem 2000 Nov;48(11):5723-30.

76. Guo X, et al. Distribution of free seleno-amino acids in plant tissue of Melilotus indica L. grown in selenium-laden soils. Ecotoxicol Environ Saf 1998 Mar;39(3):207-14.

77. Wang X, et al. Long-term exposure of HL60 cells to 1,25 dihydroxyvitamin D3 reduces their tumorigenicity; a model for cancer chemoprevention. Proc Soc Exp Biol Med 1997 Sep;215(4):399-404.

78. van den Bemd GJ, et al. Vitamin D and vitamin D analogs in cancer treatment. Curr Drug Targets 2002 Feb;3(1):85-94.

79. Vieth RL. Vitamin D supplementation, 24-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69:842-56.